Quantcast
Last updated on April 17, 2014 at 8:56 EDT

Latest Motor neuron disease Stories

2012-02-28 19:00:00

The American Academy of Neurology Foundation and The ALS Association announce the creation of the Richard Olney Clinician Scientist Development Award in ALS, named after Richard K. Olney, M.D., a leading neurologist and pioneer in clinical ALS research who died late last month of ALS, also known as amyotrophic lateral sclerosis, or Lou Gehrig´s Disease. St, Paul, Minn. (PRWEB) February 28, 2012 The American Academy of Neurology Foundation and The ALS Association are announcing the...

2012-02-28 13:00:00

Autograph Store Charity Fundraising will bring its unparalleled experience developing unique fundraising ideas to more than 100 ALS TDI events in 2012. New York, NY (PRWEB) February 28, 2012 The fundraising and development teams at Autograph Store Charity Fundraising and the ALS Therapy Development Institute (ALS TDI) are pleased to announce their national partnership for charity auctions hosted throughout 2012. After a careful vetting process, ALS TDI selected Autograph Store Charity...

2012-02-14 10:48:00

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced today that it has closed on its previously announced registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share, and 5,200,000 warrants each with an exercise price of $1.02 per share and exercisable starting six months from the issuance date for a term of five years. The company received aggregate gross proceeds of $5,200,000, which will be used for general corporate...

2012-02-14 07:30:00

CAMBRIDGE, Mass., Feb. 14, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical trial on TDI 132 (aka: fingolimod/Gilenya®) as a potential treatment for ALS (Lou Gehrig's disease). Fingolimod is currently being marketed by Novartis AG as Gilenya® as a treatment for some forms of multiple sclerosis. (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) "Getting to this point was only possible because ALS...

2012-02-01 15:05:00

TUCSON, Ariz., Feb. 1, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association's latest round of grants allocates more than $12 million to the support of 38 research projects investigating the causes of, and potential treatments for, a number of forms of neuromuscular disease. "MDA is strongly committed to funding important and exciting basic research that will serve as the basis of future therapies for neuromuscular disease," said MDA Chairman of the Board R. Rodney Howell, M.D....

2012-01-19 10:00:00

Dr. Gary McClain announces the publication of a new supplementary textbook. After the Diagnosis: How Patients React and How to Help them Cope is the first comprehensive textbook to prepare healthcare professionals to help patients to cope with these challenges. New York, NY (PRWEB) January 19, 2012 Dr. Gary McClain announces the publication of a new supplementary textbook. When patients are presented with the news that they have been diagnosed with a chronic or catastrophic medical...

2011-12-26 07:20:23

A global team of neuroscientists, led by researchers at Mayo Clinic in Florida, have found the gene responsible for a brain disorder that may be much more common than once believed. In the Dec. 25 online issue of Nature Genetics, the researchers say they identified 14 different mutations in the gene CSF1R that lead to development of hereditary diffuse leukoencephalopathy with spheroids (HDLS). This is a devastating disorder of the brain´s white matter that leads to death between ages 40...

2011-12-19 08:00:00

CAMBRIDGE, Mass., Dec. 19, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) today announced a research agreement with Biogen Idec (NASDAQ: BIIB) and UCB Pharma SA (EN Brussels: UCB) to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed. (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)...

2011-12-19 07:00:00

CARLSBAD, Calif., Dec. 19, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all Types of SMA. "SMA is a devastating disease that leads to the loss of motor neurons resulting in muscle weakness...

2011-12-15 16:25:07

Children with a rather mysterious movement disorder can have hundreds of attacks every day in which they inexplicably make sudden movements or sudden changes in the speed of their movements. New evidence reported in an early online publication from the January 2012 inaugural issue of Cell Reports, the first open-access journal of Cell Press, provides an answer for them. Contrary to expectations, the trouble stems from a defective version of a little-known gene that is important for...